Manufacturer: Emcure Pharmaceuticals Ltd
Salt Composition : Leuprolide(22.5mg)
Advanced prostatic cancer is a cancer (abnormal cell multiplication and differentiation) that originates in the prostate gland and spreads to the other parts of the body. It is characterized by the symptoms such as painful urination, decreased urine pressure, blood in the semen, bone pain, leg swelling, and weakness.
Do not receive ELIGARD 22.5MG INJECTION if you are allergic to Leuprolide, GnRH, GnRH agonist analogs.
Before receiving this medicine, inform your doctor if you have liver impairment, kidney impairment, congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, metastatic vertebral lesions, urinary tract obstruction, or diabetes.
Before receiving this medicine, inform your doctor if you have a history of seizures, epilepsy, cerebrovascular disorders, or central nervous system anomalies/tumours. ELIGARD 22.5MG INJECTION is not recommended for use in pregnant women, breastfeeding women, and children.
It should be used with caution in elderly patients (aged above 65 years). Consult your doctor before receiving.
The most common side effects associated with the use of ELIGARD 22.5MG INJECTION are general pain, reactions at the site of injection, hot flashes/sweating, gastrointestinal disorders, joint disorders, shrinking of testes, urinary disorders, infections in upper respiratory tract, and fatigue. Consult your doctor if any of these side effects worsens.
ELIGARD 22.5MG INJECTION helps in palliative treatment of advanced prostatic cancer where leuprolide works by blocking the secretion of gonadotropin releasing hormone (GnRH) following an initial stimulation, resulting in suppression of ovarian and testicular steroidogenesis (process of synthesis of steroid hormones), thereby relieving the symptoms associated with increased testosterone levels in advanced prostatic cancer.
Leuprolide has a terminal elimination half-life of approximately three hours. Leuprolide administered as a 1 mg intravenous bolus in healthy males has a mean systemic clearance between 7.6 and 8.3 L/h. Leuprolide is considered extremely safe, with low dose-related toxicity and comparatively mild adverse effects.
COMMON
Hot flashes, sweating
General pain in the body (especially joint pain and back pain)
Pain at the site of injection
Gastrointestinal disorders
Respiratory disorders
Urinary disorders
Shrinking of testicles
Extreme weakness
Headache
Joint disorders
Dizziness
Other sleep disorders
Neuromuscular disorders
Skin reactions
Flu-syndrome
Dehydration
Muscle pain
Sensation of pins and needles
Lethargy
Constipation
Sinus headache
Influenza-like illness including influenza, nasopharyngitis, nasal congestion, upper respiratory tract infection, rhinorrhea, and viral upper respiratory tract infection
Cough
Hemorrhagic cystitis
High blood pressure
Rash
Urinary tract infection
Cystitis (an inflammatory condition of bladder)
Decreased haemoglobin
COPD (chronic obstructive pulmonary disease)
Breathlessness especially on exertion
Increased frequency of urination in night
Peripheral/pitting oedema (swelling in legs and feet due to water retention)
Coronary artery disease ( heart disease) characterized by angina (chest pain)
Itching
Hair loss
Pain in testicles
Clamminess
Breast enlargement in males
Reduced libido
RARE
Stop receiving ELIGARD 22.5MG INJECTION and contact your doctor if you experience any of the following side effects:
COPD (chronic obstructive pulmonary disease)
Coronary artery disease (heart disease) is characterized by angina (chest pain)
Cerebrovascular accident/transient ischemic attack (life-threatening events related to impaired heart function)
Pneumonia (a life-threatening lung disease)
Second primary neoplasm (cancer) including basal cell carcinoma, lung neoplasm, bladder transitional cell carcinoma, malignant melanoma, squamous cell carcinoma, non-Hodgkin’s lymphoma
Contraindications to leuprolide therapy include hypersensitivity to leuprolide or any other gonadotropin-releasing hormone agonists. [13] This medication should not be used in women who are or may become pregnant. A negative pregnancy test is necessary before starting the medication.
ELIGARD 22.5MG INJECTION is not recommended for use during pregnancy. Consult your doctor before receiving.
ELIGARD 22.5MG INJECTION is not recommended for use in breastfeeding women as it can pass through milk. Consult your doctor before receiving.
Leuprolide is a medication used in the management and treatment of prostate cancer, endometriosis, uterine fibroids, precocious puberty, and other sex hormone-related conditions. It is in the GnRH agonist class of medications.
Drug-Drug Interaction: LEUPROLIDE may interact with heart rhythm problems treating drugs (quinidine, procainamide, disopyramide, amiodarone, sotalol), steroids (dexamethasone, methylprednisolone) and prednisone antibiotics (moxifloxacin), opioid pain killers (methadone) and antipsychotics (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline).
Drug-Food Interaction: No interactions found/established.
Drug-Disease Interaction: LEUPROLIDE should be used with caution in cases of liver or kidney diseases, heart diseases, recent heart attack, depression, brain tumours, electrolyte imbalance, diabetes, fits, weak bones and high cholesterol levels.
Drug-Drug Interactions Checker List:
QUINIDINE
PROCAINAMIDE
DISOPYRAMIDE
AMIODARONE
DEXAMETHASONE
METHYLPREDNISOLONE
PREDNISOLONE
MOXIFLOXACIN
METHADONE
CITALOPRAM
ESCITALOPRAM
FLUOXETINE
FLUVOXAMINE
PAROXETINE
SERTRALINE
Keep ELIGARD 22.5MG INJECTION out of reach of children
Store between 2-8°C
ELIGARD 22.5MG INJECTION will be given to you only by a doctor or nurse in a hospital, and so it is unlikely to receive an overdose. If you or anyone else accidentally receives too much of this medicine, consult your doctor immediately or visit the nearby hospital. Symptoms of overdose are shortness of breath, decreased activity, and increased scratching.
ELIGARD 22.5MG INJECTION will be administered to you only by a doctor or a nurse intramuscularly (into the muscle) or subcutaneously (under the skin). Your doctor will administer the correct dose and duration for you depending upon your age, body weight and disease condition.
What ELIGARD 22.5MG INJECTION is used for?
ELIGARD 22.5MG INJECTION for palliative treatment (relieving symptoms and minimize the associated suffering) of advanced prostatic cancer. Consult your doctor before receiving.
What side effects are seen with ELIGARD 22.5MG INJECTION?
The most common side effects associated with the use of ELIGARD 22.5MG INJECTION are general pain, reactions at the site of injection, hot flashes/sweating, gastrointestinal disorders, joint disorders, shrinking of testes, urinary disorders, infections in the upper respiratory tract, and fatigue. Consult your doctor if any of these symptoms worsens.
Who should avoid receiving ELIGARD 22.5MG INJECTION?
Do not receive ELIGARD 22.5MG INJECTION if you are allergic to leuprolide, GnRH, GnRH agonist analogs. It is not recommended for use in pregnant women, breastfeeding women, and children. Consult your doctor before receiving.
Is ELIGARD 22.5MG INJECTION safe to use in children?
ELIGARD 22.5MG INJECTION is not recommended for use in children because the safety and effectiveness of this medicine have not been established in this population. Consult your doctor before receiving.
